Remove Arcturus Remove Capital Remove Marketing
article thumbnail

TrueCar Prices IPO

socalTECH

TrueCar is trading on the NASDAQ Global Select Market as TRUE. TrueCar is venture backed by backed by USAA, Capricorn Investment Group, Upfront Ventures, Anthem Ventures, Vulcan Capital Growth Equity, Peppy Capital Partners, Arcturus Venture Capital, along with others. The company raised around $71.1M

Truecar 147
article thumbnail

Ondax Names New CEO

socalTECH

Monrovia-based Ondax , a manufacturer of holographic filters and semiconductor lasers for the industrial, defense, scientific and medical markets, announced this week that it has named Randy Heyler as its President and CEO. ONDAX is backed by Arcturus Capital, Prospector Equity Capital, and others.

Arcturus 124
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Digital Performance Raises $3.2M, Hires CEO

socalTECH

Long Beach-based Digital Performance, which develops technology for online sales efforts in the after market automotive parts sector, is announcing Monday that it has raised $3.2M The round was led by Rincon Venture Partners, and also included Arcturus Capital and Momentum Venture Management. in a Series A funding round.

Arcturus 100
article thumbnail

Zag Makes Exec Hires, Promotions

socalTECH

; Lepler has served at Brandspeak in addition to providing marketing and other expertise to a large number of other firms; and Marcus joins from Faith Communications. The firm is backed by Anthem Venture Partners, Capital One Auto Finance, GRP Partners, Arcturus Capital, Callaway Cars and the Skoll Fund. READ MORE>>

Zag 100
article thumbnail

Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More

Xconomy

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.

Equity 84